GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 174.2 BRL | +0.72% |
|
+1.13% | -9.49% |
| 04-26 | TD Cowen Adjusts Price Target on Gilead Sciences to $85 From $90 | MT |
| 04-26 | Jefferies Adjusts Gilead Sciences' Price Target to $80 From $95 | MT |
| Sales 2024 * | 27.54B 141B 37.65B | Sales 2025 * | 28B 143B 38.27B | Capitalization | 81.58B 417B 112B |
|---|---|---|---|---|---|
| Net income 2024 * | 391M 2B 534M | Net income 2025 * | 6.43B 32.9B 8.79B | EV / Sales 2024 * | 3.58 x |
| Net Debt 2024 * | 16.88B 86.35B 23.08B | Net Debt 2025 * | 9.29B 47.49B 12.69B | EV / Sales 2025 * | 3.25 x |
| P/E ratio 2024 * |
94.4
x | P/E ratio 2025 * |
12.4
x | Employees | 18,000 |
| Yield 2024 * |
4.75% | Yield 2025 * |
4.96% | Free-Float | 99.9% |
More Fundamentals
* Assessed data
More news
Latest transcript on Gilead Sciences, Inc.
More recommendations
More press releases
More news
| 1 day | +0.72% | ||
| 1 week | +1.13% | ||
| Current month | -3.83% | ||
| 1 month | -3.96% | ||
| 3 months | -10.76% | ||
| 6 months | -11.64% | ||
| Current year | -9.49% |
1 week
171.25
175.00
1 month
171.25182.55
Current year
171.25215.96
1 year
164.46215.96
3 years
132.24235.55
5 years
122.30238.80
10 years
102.29238.80
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 58 | 19-02-28 |
Andrew Dickinson
DFI | Director of Finance/CFO | 54 | 15-12-31 |
Flavius Martin
CTO | Chief Tech/Sci/R&D Officer | - | 21-04-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anthony Welters
BRD | Director/Board Member | 69 | 20-10-16 |
| Director/Board Member | 71 | 17-12-31 | |
Ted Love
BRD | Director/Board Member | 65 | 01-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 174.2 | +0.72% | 2,410 |
| 24-04-24 | 173 | +0.36% | 325 |
| 24-04-23 | 172.4 | -0.50% | 1,100 |
| 24-04-22 | 173.2 | +0.55% | 201 |
| 24-04-19 | 172.3 | -0.69% | 886 |
Delayed Quote Sao Paulo, April 25, 2024 at 09:40 am
More quotes
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
2024-05-08
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
65.42
USD
Average target price
84.25
USD
Spread / Average Target
+28.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- GILD Stock
- GILD34 Stock
